US48115J1097 - Common Stock
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Let's have a look at the top gainers and losers in the middle of the day of today's session.
DERM stock results show that Journey Medical beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Journey Medical (NASDAQ:DERM) just reported results for the fourth quarter of 2...
Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 ...
Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024...
Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET...
SCOTTSDALE, Ariz., March 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical...
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that...
Journey Medical (FBIO) said it has submitted a New Drug Application for its rosacea treatment DFD-29. The product is being developed with Dr. Reddy's (RDY). Read more here.
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea...
Journey Medical secures credit facility with SWK Holdings, allowing for borrowings of up to $20M to fund corporate operations and product development.
Provides additional capital for general corporate purposes including funding to support the potential launch of DFD-29...
On track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023...
Company generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023 GAAP...
Company to host conference call to discuss financial results and provide a corporate update on November 7, 2023 at 4:30 p.m. ET...
Study demonstrated systemic exposure of DFD-29 was significantly lower than that of Solodyn (105 mg) Data presented at 43rd Annual Fall Clinical...
Justin Smith, an insider at Journey Medical, purchased 33K shares at $2.98 per share. Net purchase activity in the past three months is 289.1K shares.
Journey Medical director discloses purchase of 15K shares worth $44.7K in recent SEC filing, alongside 8 open market buys and 2 seller trades.
Journey to receive an upfront payment of $19 million...
The Company generated total net revenues of $17.2 million in the second quarter of 2023, a 41% increase from $12.2 million in the first quarter of 2023 ...
Company to host conference call to discuss financial results and provide a corporate update on August 8, 2023 at 4:30 p.m. ET Company and Neal Bhatia, MD,...
Company to host conference call to discuss financial results and provide a corporate update the week of August 7, 2023...